Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07901764
Starting soon Not applicable

MYTP01 for Immune-Mediated Diseases

NCT07901764 · tracked via the Priya Life Science China tracker
Sponsor
Zhejiang Provincial People's Hospital
Phase
Not applicable
Started
2026-10
Last updated
2026-10-28

Condition(s) studied

IgA NephropathyKidney Transplant RecipientsLupus NephritisPrimary Membranous NephropathyANCA-associated VasculitisSystemic Lupus ErythematosusRheumatoid Arthritis (RA)Sjogren's SyndromeHashimoto Thyroiditis

Investigational drug(s) / intervention(s)

MYTP01MYTP01 Placebo

MYTP01: MYTP01 is a traditional Chinese herbal formula developed by clinical experts with the assistance of artificial intelligence (AI). It is administered orally as granules twice daily for 8 weeks in addition to standard medical treatment.

MYTP01 Placebo: MYTP01 placebo is provided as oral granules designed to match MYTP01 in appearance and packaging to maintain blinding. It is administered twice daily for 8 weeks in addition to standard medical treatment, including immunosuppressive therapy as prescribed.

Study summary

The goal of this study is to evaluate whether MYTP01, a traditional Chinese herbal formula developed by clinical experts with the assistance of artificial intelligence (AI), is effective and safe as an additional treatment for immune-mediated diseases (post-kidney transplantation, IgA nephropathy, etc.). The study also aims to explore whether MYTP01 may provide therapeutic benefits across these conditions by regulating shared immune and inflammatory processes. The main questions this study aims to answer are:

* Does MYTP01 provide clinical benefits and remain safe when used as an additional treatment for immune-mediated conditions?
* Does MYTP01 help regulate immune balance and inflammatory responses across immune-mediated disease populations?

Researchers will compare MYTP01 with a matching placebo, with both treatments given in addition to standard medical care, to evaluate clinical efficacy, safety, and potential immunomodulatory effects across immune-mediated conditions.

Participants will:

* Be enrolled in a disease-specific cohort based on their clinical condition.
* Be randomly assigned to receive either MYTP01 or placebo in addition to their usual medical treatment.
* Take the assigned study treatment twice daily for 8 weeks.
* Attend follow-up visits approximately once a month during a 12-week study period.
* Undergo clinical assessments, blood and urine tests, and evaluations of immune function and possible side effects.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18 to 65 years. * Diagnosed with one of the following conditions: (1) Kidney transplant recipients: At least 6 months after kidney transplantation, with stable graft function (eGFR variation \<20% and no recent acute rejection). (2) IgA nephropathy: Biopsy-confirmed primary IgA nephropathy within the past 5 years, with persistent disease activity despite at least 3 months of supportive treatment (UPCR 0.5-3.5 g/day and eGFR ≥ 30 mL/min/1.73 m²). * Stable immunosuppressive or other background medical treatment for at least 4 weeks before enrollment, with dose changes ≤ 20%. * Adequately controlled blood pressure (≤140/90 mmHg) and fasting blood glucose (≤6.1 mmol/L), with stable vital signs. * Willing to receive Chinese herbal treatment and undergo scheduled follow-up assessments, including T-cell subset analysis, cytokine measurements, and renal function tests. * Traditional Chinese medicine (TCM) syndrome differentiation consistent with the indications for the AI-selected herbal formula. * Female participants who are not pregnant and agree to use effective contraception during the study. * Willing and able to provide written informed consent. Exclusion Criteria: * Acute transplant rejection within the past 3 months or rapidly progressive IgA nephropathy (eGFR decline ≥30%). * Severe renal impairment (eGFR \<30 mL/min/1.73 m²) or requiring dialysis. * Severe proteinuria (\>3.5 g/day) or nephrotic syndrome. * Active infections, including opportunistic infections, active hepatitis B or C infection, or active tuberculosis. * Initiation or major dose adjustment of immunosuppressants, biologic agents, or corticosteroids, or antibiotic treatment within the past 4 weeks. * History of malignancy within the past 5 years. * Severe cardiovascular, hepatic, hematologic, or psychiatric disorders that may affect study participation or adherence. * Known allergy or hypersensitivity to any component or excipient of the study herbal formula. * Pregnant or breastfeeding women, or women planning to become pregnant during the study period. * Participation in another clinical trial during the study period.

Primary outcome measure(s)

  • Change in Estimated Glomerular Filtration Rate (eGFR) — Baseline, Week 4, Week 8, and Week 12
  • Change in 24-Hour Urinary Protein Excretion — Baseline, Week 4, Week 8, and Week 12
  • Change in Traditional Chinese Medicine Syndrome Score — Baseline, Week 4, Week 8, and Week 12

Trial sites (1)

FacilityCityRegionStatus
Zhejiang Provincial People's Hospital Hangzhou Zhejiang

More Zhejiang Provincial People's Hospital trials in China

Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC Starting soon
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study Recruiting
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study Recruiting
An Exploratory Study to Confirm Efficacy of Modified Deep Cervical Lymphovenous Anastomosis (LVA) in Alzheimer's Disease/ Parkinson's Disease Recruiting
Revascularization Effect on CSVD Burden in Carotid Artery Stenosis Recruiting

Other trials for the same condition

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE Recruiting
IgA Nephropathy Biomarkers Evaluation Study (INTEREST) Recruiting
Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE) Starting soon
Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV Starting soon
Correlation of Microbiome and Metabonomics With IgA Nephropathy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07901764 on ClinicalTrials.gov ↗ ← All trials in China